Table 2.
Baseline laboratory parameters and cardiovascular intermediate markers of study participants, by treatment group
| Parameters | Total (n=278) | Placebo (n=140) | Lanthanum (n=138) |
|---|---|---|---|
| Hemoglobin (g/L) | 124.3±16.1 | 123.8±16.2 | 124.8±16.0 |
| Albumin (g/L) | 38.9±4.3 | 38.7±4.0 | 39.1±4.5 |
| Bicarbonate (mmol/L) | 23.5±3.5 | 23.7±3.2 | 23.3±3.7 |
| Urea (mmol/L) | 16.0±5.2 | 15.8±5.1 | 16.2±5.4 |
| Creatinine (µmol/L)a | 221.4±59.4 | 219.2±58.5 | 223.6±60.3 |
| eGFR (ml/min per 1.73 m2)b | 26.6±8.3 | 27.0±8.6 | 26.1±8.1 |
| Uric acid (mmol/L) | 0.46±0.11 | 0.47±0.11 | 0.45±0.11 |
| Glucose (mmol/L) | 6.3±3.0 | 6.3±2.8 | 6.4±3.1 |
| Calcium (mmol/L) | 2.32±0.13 | 2.32±0.12 | 2.33±0.14 |
| Phosphate (mmol/L) | 1.25±0.20 | 1.26±0.18 | 1.24±0.22 |
| ALP (U/L) | 88.9±30.5 | 92.0±29.8 | 85.8±31.1 |
| PTH (pmol/L)c | 12.0 (7.2–17.8) | 11.9 (7.4–16.8) | 12.6 (6.4–19.4) |
| 25-Hydroxyvitamin D (nmol/L) | 70.1±30.7 | 68.9±29.0 | 71.3±32.6 |
| 1,25-Dihydroxyvitamin D (pmol/L) | 77.8±26.8 | 75.5±26.7 | 80.3±26.9 |
| C-terminal FGF23 (RU/ml) | 221.1 (154.3–334.1) | 225.1 (160.5–327.1) | 220.7 (151.7–353.1) |
| Intact FGF23 (pg/ml) | 133.0 (89.1–202.0) | 136.0 (89.4–201.4) | 124.8 (88.9–208.5) |
| Urinary phosphate excretion (mmol/24 h) | 24.4±11.4 | 26.1±12.6 | 22.7±9.9 |
| Cholesterol (mmol/L) | 4.5±1.1 | 4.4±1.1 | 4.6±1.1 |
| Triglyceride (mmol/L) | 2.1±1.4 | 2.0±1.2 | 2.2±1.5 |
| C-reactive protein (mg/L) | 4.7±6.3 | 4.7±6.4 | 4.8±6.3 |
| Protein excretion (mg/24 h) | 718 (182–1710) | 823 (200–1720) | 535 (120–1710) |
| Urine ACR (mg/mmol)d | 68 (20–139) | 74 (23–141) | 54 (16–138) |
| PWV (m/s) | 10.8±3.6 | 10.8±3.6 | 10.8±3.6 |
| Augmentation index (%) | 27.3±9.6 | 26.9±10.4 | 27.5±9.0 |
| Aortic calcificatione | 191 (81.3%) | 90 (76.9%) | 101 (85.6%) |
| Agatston scoree | 1535 (63–5744) | 839 (11–3839) | 2133 (278–6081) |
Results presented as mean±SD, number (percentage) or median (interquartile range). ALP, alkaline phosphatase; ACR, albumin-creatinine ratio.
a
Conversion to mg/dl: multiply by 0.0113.
b
eGFR calculated using CKD–Epidemiology Collaboration equation.
c
Conversion to pg/ml: multiply by 9.4.
d
Conversion to mg/g: multiply by 8.85.
e
A total of 235 participants had usable CT scans to determine aortic calcification (118 lanthanum, 117 placebo).